Please use this identifier to cite or link to this item:
|Title:||Impact of Epstein-Barr virus in the clinical evolution of patients with classical Hodgkin's Lymphoma in Brazil|
|Authors:||Souza, Eni M. [UNIFESP]|
Baiocchi, Otavio Carvalho Guimarães [UNIFESP]
Zanichelli, Maria A.
Alves, Antonio C. [UNIFESP]
Assis, Marianne G. [UNIFESP]
Eiras, Daniel P. [UNIFESP]
Dobo, Cristine [UNIFESP]
Oliveira, Jose S. R. [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
Brigadeiro State Hosp
|Citation:||Hematological Oncology. Chichester: John Wiley & Sons Ltd, v. 28, n. 3, p. 137-141, 2010.|
|Abstract:||Introduction: Classical Hodgkin's Lymphoma (cHL) has been frequently associated with Epstein Barr virus (EBV), which can be found in a latent pattern in Reed-Sternberg (RS) cells. However, the impact of the presence of EBV in RS cells and its prognosis are still controversial. We analysed the presence of EBV in RS cells and its influence in the clinical evolution of patients with cHL treated in two public hospitals in the city of São Paulo, Brazil.Materials and Methods: We selected 97 patients with cHL from 1994 to 2004. Patients were only included in this study if they had (1) >18 years, (2) negative HIV serology, (3) undergone similar chemotherapy protocols, (4) paraffin blocks available with enough material for systematic review and histological reclassification and for detection of EBV in RS cells by in situ hybridization and immunohistochemistry and (5) clinical, epidemiological and laboratorial parameters available after a thorough chart review.Results: EBV was identified in 52.5% of the cases. Mixed cellularity (MC) subtype was more common in EBV-related tumours (25.5%) (p =0.005). There was no difference on age, gender, stage and the presence of B symptoms between the two groups. the presence of EBV did not influence event free survival (EFS) (p =0.38) or overall survival (OS) (p = 0.80) with a median follow-up of 80 months.Conclusion: We demonstrate that the prevalence of EBV-related cHL in this Brazilian population is 52.5% and, that, the presence of EBV does not change the clinical evolution and OS of patients treated with similar chemotherapy protocols. Copyright (C) 2010 John Wiley & Sons, Ltd.|
|Appears in Collections:||Em verificação - Geral|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.